Anemia Treatment Market is projected to total US$ 14.9 Billion by 2028 at a CAGR of 6.9%

In 2022, it’s anticipated that the Anemia Treatment Market would surpass US$ 10.0 billion. By 2028, the market is anticipated to be worth US$14.9 billion, with sales rising at a strong CAGR of 6.9%.

The majority of the demand for anaemia therapy, according to a recent report by Future Market Insights, is caused by the condition as a result of one or more chronic conditions.

Demand for anaemia treatment is largely driven by chronic kidney disease (CKD), one of the non-communicable chronic diseases responsible for the demographic shift of emerging regions. The rising popularity of combination therapy is also having a significant impact on the market for anaemia therapies. Growing usage of antibiotics, metal chelating agents, erythropoietin-stimulating drugs, and vitamin and iron supplements in combination therapy is acknowledged as a key factor boosting the outlook for the anaemia treatment market in the years to come.

Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-8966

Vitamin Supplements Gain Significant Traction for Anemia Treatment

A surge in R&D investments is prominently improving scope of anemia treatment. Moreover, a rising number of pipeline drugs and promising potential of biosimilars will contribute to the demand for anemia treatment. However, high price point associated with biologics continues to mask their superior treatment efficacy over conventional medications.

More than 75% of anemia treatment market revenue is accounted by medications, of which, ESAs (erythropoietin stimulating agents) remain bestselling. Blood transfusion also cited as an important type of anemia treatment, contributing to the market growth. However, the demand for former is poised for a robust double-digit yearly growth in 2021 and ahead.

Lucrative emergence of ESAs and soaring consumption of other biosimilar medications are likely to introduce new investment opportunities in anemia treatment market. Extensive availability, accessibility, and economic price point of biosimilar drugs is strongly backed by an increasing number of FDA approvals. This according to FMI will significantly contribute in improvement of CKD, thereby bolstering the revenue of anemia treatment market. FDA recently issued an approval to a biosimilar drug by Pfizer for use in anemia treatment – Retacrit (epoetin alfa-epbx).

Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-8966

Over 55% of dietary supplements consumed as a part of anemia treatment are vitamin supplements. An increasing number of iron deficient patients will reportedly result in rapid demand growth of iron supplements in years to come, posing strong competition to that of vitamin supplements in the anemia treatment market. Currently, almost 60% of the medications and dietary supplements for anemia treatment is available at institutional pharmacies. The report also points to a gradually expanding share of retail pharmacies in the near future.

Just-under a third of the global demand for anemia treatment is raised by North American patients, whereas more than a third of the total demand is accounted collectively by East and South Asia. Europe is also cited as one of the key regional markets for anemia treatment providers.

Product-based Business Models Emerge as a Key Competitive Strategy

The consistent quest for therapeutically effective ESAs, dietary supplements, antibiotics, and other biologics to be used in anemia treatment continues to create attractive avenues in the R&D realm. Leading drug manufacturers are investing efforts in launching novel products and upgrading their existing consumable product portfolios. Amgen’s epoetin alpha has been a breakthrough product since its launch in the CKD treatment landscape and growing adoption continues to benefit the company.

Besides augmenting R&D investments, prominent players in anemia treatment market are also focusing on strategic agreements and partnerships – further paving the way for development of anemia treatment drugs. Emergence of partnership-based models in the competitive landscape of anemia treatment market is likely to reshape R&D structure in the anemia treatment market. The report prompts at major investment opportunities arising in open collaboration strategies. A number of drug manufacturers are also opting for partnerships with regional distribution leaders to form effective product-based distribution channels, particularly targeting developing regional markets.

For more Report Customization, connect with us at@ https://www.futuremarketinsights.com/customization-available/rep-gb-8966

Anemia Treatment Market by Category

By Treatment:

• Medications
• Dietary Supplements

By Disease:

• Normocytic anemia
• Microcytic anemia
• Macrocytic anemia

By Distribution Channel:

• Institutional Pharmacies
• Retail Pharmacies
• Mail Order Pharmacies

Key Companies Profiled:

• Amgen Inc.
• Hoffmann-La Roche Ltd.
• Novartis AG
• Pfizer Inc.
• Janssen Pharmaceuticals, Inc.
• Teva Pharmaceutical Industries Ltd.
• AMAG Pharmaceuticals
• Rockwell Medical
• Akebia Therapeutics
• Vifor Pharma Management Ltd.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭@ https://www.futuremarketinsights.com/checkout/8966

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 07-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs